Michael Milos Thornton - 09 Dec 2022 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Chief Technology Officer
Signature
/s/ Michael M. Thornton by Mark Busch, attorney-in-fact
Issuer symbol
NDRA
Transactions as of
09 Dec 2022
Net transactions value
+$5,100
Form type
4
Filing time
13 Dec 2022, 15:00:20 UTC
Previous filing
24 Aug 2022
Next filing
01 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NDRA Common Stock Purchase $5,100 +1,500 +8.5% $3.40 19,139 09 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 9, 2022, the Issuer effected a 1-for-20 reverse stock split (the "Reverse Stock Split") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.